Clicky

CSL Limited  (CSL) News

Date Title
May 28 KMDA vs. CSLLY: Which Stock Should Value Investors Buy Now?
May 23 CSL (ASX:CSL) Secures NICE Approval For Sparsentan Use In NHS England
May 23 England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
May 5 CSL (ASX:CSL) Hosts Shareholder Information Meeting for Investor Clarity
Apr 16 Weekly Picks: 🧠 Alphabet’s AI edge, CSL’s pricing power, and a chip underdog
Apr 13 Are CSL Limited's (ASX:CSL) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Mar 3 Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
Feb 28 BMRN or CSLLY: Which Is the Better Value Stock Right Now?
Feb 20 CSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks of Hereditary Angioedema (HAE)
Feb 14 Here's What Analysts Are Forecasting For CSL Limited (ASX:CSL) After Its Half-Yearly Results
Feb 14 European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
Feb 13 European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
Feb 12 BMRN vs. CSLLY: Which Stock Is the Better Value Option?
Dec 9 CSL Behring Scales Global HCP Engagement and Attracts new HCPs with the ON24 Platform
Oct 2 EXEL vs. CSLLY: Which Stock Is the Better Value Option?
Oct 1 CSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
Sep 30 Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
Sep 30 Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
Sep 25 CSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
Sep 24 Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia